PT  - JOURNAL ARTICLE
AU  - Lucía Marín Barrera
AU  - Cecilia López Ramírez
AU  - José Luis López-Campos
AU  - Carmen Calero Acuña
AU  - Alberto Fernández-Villar
AU  - Cristina Represas Represas
AU  - Cristina Ramos Hernández
AU  - Ricard Casamor
TI  - Pharmacological treatment of COPD in the on-sint cohort
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P536
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P536.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P536.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - OBJECTIVE:Describe pharmacological treatment of COPD in patients included in the On-Sint cohort, both when diagnosed and at present.METHODS:Retrospective,multicenter observational study where patient data were collected from single medical visit and by reviewing medicals records.The cohort On-Sint was formed by adult COPD patients,smokers or ex-smokers(≥10 packs-years),who were regularly followed-up by 263 primary care physicians(PC) or 93 Pulmonologists(P).We describe and compare the pharmacological treatment(by therapeutic groups)that patients received upon diagnosis and at present stratified by the GOLD classification.Quantitative data expressed as mean(standard deviation)RESULTS:1214 patients met inclusion criteria(age of 66.4(9.7)years,78.7% male,857(70.6%)by PC).The average time interval from diagnosis to inclusion was 8(7.2)years.The different therapeutic group that each patient received upon diagnosis and at present according to 2010 GOLD stages,is indicated in the table.View this table:CONCLUSIONS:On-Sint cohort has detected an increase in the use of LABD and ICS,although the indication seems to be more consistent with the functional severity.Mucolytics are still excessively used.The use of all groups of treatment is lower for those with unknown GOLD stage.